Novel Targetable BIOmarkers in ANorexia NervosA

Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · May 22, 2023

Keywords

ClinConnect Summary

**Clinical Trial Summary: Novel Targetable BIOmarkers in Anorexia Nervosa**

This clinical trial is exploring potential new treatments for anorexia nervosa, specifically looking at certain proteins and inflammation markers in the body. Researchers want to understand how these markers, including Growth Differentiation Factor-15 (GDF-15) and various inflammatory substances, might help in treating this condition. By comparing the levels of these markers in people with anorexia to those in healthy individuals, the study aims to learn more about how and where they are produced in the body.

To participate in this study, you need to be an adult aged 18 to 60 with a confirmed diagnosis of anorexia nervosa, either in a non-exercising or exercising subtype, and have a low body mass index (BMI). The study is currently looking for 16 healthy volunteers for comparison. Participants will undergo tests that involve blood samples and possibly cerebrospinal fluid analysis. It’s essential to note that those with certain health conditions or who have recently used certain medications might not be eligible. This study is a step towards finding more effective treatments for anorexia, and your involvement could contribute valuable information to this important area of research.

Gender

ALL

Eligibility criteria

• • N=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive type, non-exercising subtype
• Inclusion criteria:
• • Age 18-60 years
• • Written informed consent
• • BMI 10-16 kg/m2
• • N=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive type, exercising subtype will be included in this study.
• Inclusion criteria:
• • Age 18-60 years
• • Written informed consent
• • BMI 10-16 kg/m2
• • N=16 control participants, sex- and age-matched to the individual anorexia nervosa patients.
• Inclusion criteria:
• • Age 18-60 years
• • Written informed consent
• • BMI 19-24.9 kg/m2
• Exclusion Criteria:
• • Use of antibiotics within the last 31 days
• • Current illicit drug abuse including daily marijuana or CBD (cannabidiol) consumption (≤ 24 g of alcohol per day allowed)
• • Any kind of severe chronic disease other than AN (e.g. active cancer disease)
• • Severe renal impairment (e.g. estimated glomerular filtration rate \<30 ml/min/m2) if resulting from another disease than AN
• • Known liver cirrhosis or other severe liver impairment if resulting from another disease than AN
• • Acute upper respiratory tract infection within the last 31 days
• • Uncontrolled dysthyroidism
• • Uncontrolled hypertension
• • Current pregnancy/lactation or current treatment for in vitro fertilization
• • Inability to understand the study information, to sign the consent form and to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.